89bio, Inc.

NASDAQ•ETNB

執行長: Mr. Rohan Palekar

板塊: Healthcare

行業: Biotechnology

上市日期: 2019-11-11

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

聯絡資訊

142 Sansome Street, Second Floor, San Francisco, CA, 94104, United States

415-432-9270

www.89bio.com

市值

$2.20B

本益比 (TTM)

-7.8

股息率

52周最高

$15.06

52周最低

$4.16

52周範圍

98%

排名70Top 99.2%

1.1

F-Score

改良版 Piotroski 分析

基於 7 年期基本面

疲弱 • 1.1 / 9 分

評分區間 (0-9)

8-9: 價值優異

6-7: 基本面強勁

4-5: 整體穩健

0-3: 表現疲弱

資料區間: 2019-2025

財務儀表板

Q2 2025 數據

營業收入

$0.00+0.00%

近4季度走勢

每股收益

-$0.71+47.92%

近4季度走勢

自由現金流

-$100.43M+64.19%

近4季度走勢

2025 Q2 財報亮點

核心亮點

R&D Spending Rises Sharply Research and development expenses 168.3M USD for six months, up 82.4%, reflecting progression of Phase 3 ENLIGHTEN clinical trials.

Substantial Capital Raise Completed Net cash provided by financing 289.6M USD for six months, driven by 269.9M USD public offering and ATM sales.

Liquidity Position Strengthened Cash, equivalents, marketable securities 561.2M USD as of June 30, 2025, expected to fund operations for at least one year.

關注風險

Operating Losses Accelerate Significantly Net loss 182.8M USD for six months, up 83.4%; accumulated deficit reached 1.007B USD, requiring substantial future capital.

Clinical Trial Enrollment Challenges ENLIGHTEN-Fibrosis trial experiencing higher screen failures, potentially delaying expected topline histology data reporting timeline.

Israeli Tax Liability Risk Formal assessment order received from ITA asserting $26.0M tax liability plus $3.9M penalties; ultimate resolution uncertain.

未來展望

SHTG Topline Data Expected Q1 2026 Expect to report topline data from the ENTRUST Phase 3 SHTG trial in the first quarter of 2026, following study completion.

MASH Phase 3 Data Milestones ENLIGHTEN-Fibrosis histology topline data anticipated H1 2027; ENLIGHTEN-Cirrhosis data expected in 2028 for F4 patients.

ATM Facility Remaining Capacity Approximately $82.8M remains available for future common stock sales under the 2023 ATM Facility for liquidity management.

同行對比

營業收入 (TTM)

GLPG

$1.26B

+303.5%

TVTX

$490.73M

+110.5%

RCUS

$247.00M

-4.3%

毛利率 (最新季度)

LQDA

101.7%

+29.3pp

AGIO

96.9%

-4.3pp

BEAM

95.0%

-471.3pp

關鍵指標

股票代碼	市值	本益比 (TTM)	股東權益報酬率 (TTM)	負債率
IBRX	$8.00B	-21.9	64.3%	175.0%
COGT	$5.90B	-7.5	-100.2%	27.0%
TVTX	$3.78B	-73.6	-79.2%	56.2%

長期趨勢

近4季度

營業收入

淨利

營運現金流

4季度營業收入複合增長率

N/M

營業收入波動較大

4季度淨利複合增長率

N/M

盈利狀態轉變

現金流穩定性

現金流需要關注

深度研究

財務數據

電話會議

財務報告

新聞

損益表

資產負債表

現金流量表

財務比率

變化率

損益表	過去12個月

無資料